Salicylic Acid-based Polymeric CEST Contrast Agents for Molecular Imaging of Prostate-specific Membrane Antigen

Case ID:

C12998

Disclosure Date:

4/7/2014

We have discovered that a salicylic acid (SA) analog when grafted on a polymeric platform is able to produce significantly enhanced contrast in MR images detectable through chemical exchange saturation transfer (CEST). That SA modified polymeric platform (SA PolyCEST), has been further modified with Glu-Lysine urea, an inhibitor of Prostate-specific membrane antigen (PSMA), a cell surface protein that is over expressed in most prostate cancers, including hormone-refractory and metastatic disease and tumor neovasculature. The PSMA targeted SA PolyCEST retains it high CEST contrast sensitivity as well high binding affinity for PSMA. Using this PSMA-targeted SA PolyCEST, we have demonstrated the first example of in vivo PSMA-specific CEST contrast enhancement in mouse xenografts. This SA PolyCEST platform can also be used for other receptor-based MR imaging.

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
SALICYLIC ACID-BASED POLYMERIC CEST CONTRAST AGENTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF	PCT: Patent Cooperation Treaty	United States	15/764,316	10,688,198	3/28/2018	6/23/2020	9/29/2036	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/24712

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Clinical and Disease Specializations > Oncology,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Jeanine Pennington

jpennin5@jhmi.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF